Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MM

Phase 1

Conditions: Multiple Myeloma in Relapse
Multiple Myeloma Progression

Interventions: Biological: anti-CD19/BCMA CAR-T cells
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2018-10-16

Last Posted Date: 2018-10-16

Lead Sponsor: Peng Liu

Target Recruit Count: 20

Registration Number: NCT03706547

Locations: 🇨🇳
Department of Hematology ,Fudan University Zhongshan Hospital, Shanghai, China

Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma

Phase 1

Suspended

Conditions: Diffuse Large B-Cell Lymphoma Unclassifiable
Intravascular Large B-Cell Lymphoma
Primary Mediastinal (Thymic) Large B-Cell Lymphoma
T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
CD20 Positive
B-Cell Non-Hodgkin Lymphoma
Aggressive Non-Hodgkin Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Doxorubicin Hydrochloride
Biological: Nivolumab
Drug: Prednisone
Other: Quality-of-Life Assessment
Biological: Rituximab
Drug: Vincristine Sulfate

First Posted Date: 2018-10-15

Last Posted Date: 2022-08-15

Lead Sponsor: Northwestern University

Target Recruit Count: 30

Registration Number: NCT03704714

Locations: 🇺🇸
Northwestern University- Lake Forest Hospital, Lake Forest, Illinois, United States
🇺🇸
Northwestern Medicine: Delnor, DuPage, Warrenville, Kishwaukee (West Region), Warrenville, Illinois, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States

and more 1 locations

Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Adults With Refractory Large B-cell Lymphoma

Phase 1

Terminated

Conditions: Relapsed/Refractory Large B-cell Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Biological: Axicabtagene Ciloleucel
Biological: Utomilumab

First Posted Date: 2018-10-12

Last Posted Date: 2024-06-28

Lead Sponsor: Kite, A Gilead Company

Target Recruit Count: 15

Registration Number: NCT03704298

Locations: 🇺🇸
Columbia University Medical Center, New York, New York, United States
🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 2 locations

Cyclophosphamide as Graft-versus-host Prophylaxis After Allogeneic Stem Cell Transplantation for Multiple Myeloma

Phase 2

Conditions: Multiple Myeloma

Interventions: Drug: Cyclophosphamide

First Posted Date: 2018-10-09

Last Posted Date: 2021-08-23

Lead Sponsor: Universitätsklinikum Hamburg-Eppendorf

Target Recruit Count: 37

Registration Number: NCT03700450

Locations: 🇩🇪
University Medical Center Hamburg-Eppendorf, Hamburg, Germany
🇩🇪
Universitätsklinikum Heidelberg, Heidelberg, Germany
🇩🇪
Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Germany

Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS

Phase 2

Terminated

Conditions: Myelodysplastic Syndromes
Acute Myeloid Leukemia

Interventions: Biological: rivogenlecleucel
Drug: Cyclophosphamide
Drug: rimiducid
Procedure: haplo-HSCT

First Posted Date: 2018-10-09

Last Posted Date: 2023-09-29

Lead Sponsor: Bellicum Pharmaceuticals

Target Recruit Count: 1

Registration Number: NCT03699475

Locations: 🇺🇸
TriStar Bone Marrow Transplant, LLC, Nashville, Tennessee, United States
🇺🇸
Methodist Healthcare System of San Antonio Clinical Trials Office, San Antonio, Texas, United States

Clinical Trial of Safety, Tolerability and Antitumor Activity of Genetically Engineered T Cells in Combination With Anti-Cancer Agents in Relapsed and Refractory Synovial Sarcoma Expressing New York Esophageal Antigen-1 (NY-ESO-1) and/or LAGE-1a

Phase 2

Withdrawn

Conditions: Neoplasms

Interventions: Drug: GSK3377794
Drug: Pembrolizumab
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2018-10-05

Last Posted Date: 2019-10-29

Lead Sponsor: GlaxoSmithKline

Registration Number: NCT03697824

Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma

Phase 1

Recruiting

Conditions: Lymphoma
Lymphoma, B-Cell
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases

Interventions: Biological: iC9-CAR19 T cells
Drug: Bendamustine
Drug: Fludarabine
Drug: AP1903
Drug: Cyclophosphamide

First Posted Date: 2018-10-05

Last Posted Date: 2024-10-24

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 30

Registration Number: NCT03696784

Locations: 🇺🇸
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States

Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation

Phase 2

Active, not recruiting

Conditions: GVHD
Hematologic Neoplasms

Interventions: Drug: Cyclophosphamide
Drug: Methotrexate
Drug: abatacept
Drug: Tacrolimus

First Posted Date: 2018-09-21

Last Posted Date: 2024-12-27

Lead Sponsor: Dimitrios Tzachanis, MD PhD

Target Recruit Count: 43

Registration Number: NCT03680092

Locations: 🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States

A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma

Phase 1

Completed

Conditions: B-cell Non-Hodgkin Lymphoma

Interventions: Drug: Mosunetuzumab
Drug: Cyclophosphamide
Drug: Polatuzumab Vedotin
Drug: Rituxumab
Drug: Doxorubicin
Drug: Prednisone
Drug: Vincristine
Drug: Tocilizumab

First Posted Date: 2018-09-19

Last Posted Date: 2024-12-18

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 117

Registration Number: NCT03677141

Locations: 🇺🇸
University of Alabama Birmingham, Birmingham, Alabama, United States
🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸
University of California; Moores Cancer Center, La Jolla, California, United States

and more 38 locations

Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR

Phase 1

Recruiting

Conditions: Acute Lymphoblastic Leukemia, Adult
Acute Lymphoblastic Leukemia, Pediatric
Chronic Lymphocytic Leukemia
Diffuse Large B Cell Lymphoma
Follicular Lymphoma
Mantle Cell Lymphoma

Interventions: Biological: CD19.CAR T Cells
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2018-09-18

Last Posted Date: 2024-07-29

Lead Sponsor: University Hospital Heidelberg

Target Recruit Count: 68

Registration Number: NCT03676504

Locations: 🇩🇪
University Hospital Heidelberg, Heidelberg, Germany

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy